Drugs / PANVAC-F
PANVAC-F
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00088413 | Jul 2004 → Apr 2018 | adenocarcinoma, breast cancer, colorectal cancer, ovarian carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT00179309 | Sep 2005 → Feb 2013 | breast cancer | National Cancer Institute (NCI) | Completed | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PANVAC-F | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00088413 ↗ |
| Known as | PANVAC fowlpox | “The PANVAC-V (PANVAC vaccinia) priming vaccine and PANVAC-F (PANVAC fowlpox) boosting vaccine contain human genes that cause production of CEA and MUC-1” NCT00088413 ↗ |
| Known as | PANVAC(TM)-F | “PANVAC(TM)-F (fowlpox) s.c. scheduled on days 15, 29, and 43 then every 28 days for up to 12 vaccines” NCT00088413 ↗ |
| Modality | Vaccine | “This is a non-randomized three cohort, pilot trial of pox viral vaccines” NCT00088413 ↗ |
| Route | Subcutaneous | “PANVAC(TM)-F (fowlpox) s.c. scheduled on days 15, 29, and 43 then every 28 days for up to 12 vaccines” NCT00088413 ↗ |